A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Conditions: Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma Intervention: Drug: YY-20394 Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials